

Orthocell receives Chinese patent covering its Celgro™ SMART graft™

- Further Chinese patent granted for Celgro™ soft tissue reconstruction platform
- Patent relates to the method of manufacture of novel bio-scaffolds to aid in the surgical repair of soft tissue injuries such as tendon, cartilage, bone and soft tissue, as well as the delivery of stem cells to relevant surgical sites
- Celgro™ patents have been previously granted in the US, Canada, Singapore, China and New Zealand

Perth, Australia; 17th June 2016: Regenerative medicine company Orthocell Limited has today announced it has been granted a further Chinese patent for its CelGro™ collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled “Method for Producing a Collagen Membrane and Uses Thereof” Chinese Patent Application provides important further IP for the Celgro™ product platform.

“This patent is an important addition to our current Chinese patent covering CelGro™ and further strengthens our international patent position for our soft tissue reconstruction platform technology”, Orthocell Managing Director Paul Anderson said, “it comes at a perfect time for the Company as we move our products through the registration processes in China and internationally.”

Celgro™ was developed to address many of the problems with existing bio-scaffolds with the result that Celgro™ boasts superior tissue in-growth and repair qualities, while exhibiting strong mechanical properties, which can be tuned to accommodate the needs of the specific tissue repair. Unlike many synthetic and biologic tissue repair devices approved globally, it is highly compatible with human tissue, is resorbed into the tissue, guiding and generating a higher quality tissue repair.

CelGro™ is manufactured in Australia, from Australian sourced raw materials which are of the highest quality available internationally and offers significant commercial potential in its existing addressable markets of bone, tendon and cartilage, as well as much wider applications in general surgical and urogynecological soft tissue reconstructive applications.

CelGro™ has been shown to significantly improve tissue in-growth and repair as well as support the restructuring of damaged tissue in the body. Pipeline opportunities are also in development for applications within the general surgical and Urogynecological specialities, amongst others.

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited, Managing Director

P: (08) 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Gavin Lower

Buchan Consulting

P: (03) 8866 1215 / 0414 796 726

E: glower@buchanwe.com.au

P: 0417 382 391

E: rwilson@buchanwe.com.au

Investor Relations

Rebecca Wilson

Buchan Consulting

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.